It was confirmed that the variant for greater weight loss effectiveness and the variant for side effects tend to act together, meaning that a better drug response was often accompanied by more severe nausea
In turn, use of these medications has skyrocketed
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
However, this difference was not observed in our study
(3) insufficient sample size in some subgroups (e.g., 54 cases in the 360 days
Activation of tubular epithelial cells in diabetic nephropathy
